Skip to main content

Sabra Reports Third Quarter 2024 Results; Updates 2024 Guidance

Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the third quarter of 2024.

THIRD QUARTER 2024 RESULTS AND RECENT EVENTS

  • Results per diluted common share for the third quarter of 2024 were as follows:
    • Net Income: $0.13
    • FFO: $0.34
    • Normalized FFO: $0.35
    • AFFO: $0.36
    • Normalized AFFO: $0.37
  • EBITDARM Coverage Summary:
    • Skilled Nursing/Transitional Care: 1.94x
    • Senior Housing - Leased: 1.37x
    • Behavioral Health, Specialty Hospitals and Other: 3.68x
  • Same store managed senior housing Cash NOI increased 17.8% on a year-over-year basis.
  • As previously announced, in the third quarter of 2024, Sabra closed on the $75.8 million acquisition of two managed senior housing communities operated by the Leo Brown Group, with an initial expected cash yield of 8.1%. Additionally, subsequent to quarter end, Sabra closed on another managed senior housing community operated by the Leo Brown Group for $24.0 million with an initial expected cash yield of 8.6%.
  • As previously announced, in the third quarter of 2024, Sabra closed on the disposition of four skilled nursing facilities for gross proceeds of $34.9 million with a trailing twelve-month cash yield of 4.0%.
  • This year through September 30, 2024, Sabra has utilized the forward feature under its at-the-market equity offering program to allow for the sale of up to 7.3 million shares at an initial weighted average price of $15.41 per share, net of commissions. As of September 30, 2024, 2.2 million shares remained outstanding under the forward sale agreements, with an initial weighted average price of $16.77 per share, net of commissions.
  • As of September 30, 2024, Net Debt to Adjusted EBITDA was 5.30x.
  • On October 31, 2024, Sabra’s Board of Directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 29, 2024, to common stockholders of record as of the close of business on November 15, 2024.

2024 GUIDANCE

Sabra is updating its 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):

Updated Guidance

  • Net Income: $0.48 - $0.49
  • FFO: $1.35 - $1.36
  • Normalized FFO: $1.39 - $1.40
  • AFFO: $1.41 - $1.42
  • Normalized AFFO: $1.43 - $1.44

Previous Guidance

  • Net Income: $0.48 - $0.51
  • FFO: $1.33 - $1.36
  • Normalized FFO: $1.36 - $1.39
  • AFFO: $1.39 - $1.42
  • Normalized AFFO: $1.41 - $1.44



    Guidance ranges assume year-over-year same store Cash NOI growth in the mid-to-high teens for the managed senior housing portfolio. Guidance also incorporates all announced investment and disposition activity, as well as announced activity under the at-the-market equity offering program. Guidance does not assume additional investment, disposition or capital transactions beyond those already disclosed.



    The foregoing guidance ranges reflect management’s view of current and future market conditions. There can be no assurance that the Company’s actual results will not differ materially from the estimates set forth above. Except as otherwise required by law, the Company assumes no, and hereby disclaims any, obligation to update any of the foregoing guidance ranges as a result of new information or new or future developments.

Commenting on the third quarter’s results, Rick Matros, CEO and Chair, said, “It feels good to be providing essentially the same update as the last several quarters. Skilled nursing and managed senior housing continue to see higher occupancy and margins. EBITDARM coverage for our skilled nursing portfolio has surpassed 2019 levels, while our triple net senior housing portfolio is approaching that milestone. Among our key triple-net relationships, the only tenant that saw a sequential coverage decline was Avamere, but that was specifically due to the percentage rent we have been collecting as performance improves. Avamere’s coverage remains healthy, and the lease restructure has worked out exactly as anticipated.

Leverage continues to tick down. Investments for the quarter and subsequent to quarter end totaled roughly $100 million, including those previously announced. Our investment pipeline has seen increased activity, and we are currently reviewing more potential investments than we have seen all year.

Additionally, we have increased the midpoint of our guidance, which implies year-over-year earnings growth of more than 6% for the full year.”

LIQUIDITY

As of September 30, 2024, we had approximately $947.8 million of liquidity, consisting of unrestricted cash and cash equivalents of $63.0 million, available borrowings under our revolving credit facility of $847.4 million and $37.4 million related to shares outstanding under forward sale agreements under our ATM program. As of September 30, 2024, we also had $386.7 million available under the ATM program.

CONFERENCE CALL AND COMPANY INFORMATION

A conference call with a simultaneous webcast to discuss the 2024 third quarter results will be held on Friday, November 1, 2024, at 10:00 am Pacific Time. The webcast URL is https://events.q4inc.com/attendee/444925126. The dial-in number for U.S. participants is (888) 880-4448. For participants outside the U.S., the dial-in number is (646) 960-0572. The conference ID number is 1382596. A digital replay of the call will be available on the Company’s website at www.sabrahealth.com. The Company’s supplemental information package for the third quarter will also be available on the Company’s website in the “Investors” section.

ABOUT SABRA

As of September 30, 2024, Sabra’s investment portfolio included 373 real estate properties held for investment (consisting of (i) 233 skilled nursing/transitional care facilities, (ii) 39 senior housing communities (“senior housing - leased”), (iii) 68 senior housing communities operated by third-party property managers pursuant to property management agreements (“senior housing - managed”), (iv) 18 behavioral health facilities and (v) 15 specialty hospitals and other facilities), 14 investments in loans receivable (consisting of three mortgage loans and 11 other loans), five preferred equity investments and two investments in unconsolidated joint ventures. As of September 30, 2024, Sabra’s real estate properties held for investment included 37,793 beds/units, spread across the United States and Canada.

FORWARD-LOOKING STATEMENTS SAFE HARBOR

This release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. These statements may be identified, without limitation, by the use of “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. Examples of forward-looking statements include all statements regarding our expectations regarding earnings growth; and our other expectations regarding our future financial position (including our earnings guidance for 2024, as well as the assumptions set forth therein), our expectations regarding occupancy, results of operations, cash flows, liquidity, business strategy, growth opportunities, potential investments and dispositions and our expectations regarding our investment activity, and plans and objectives for future operations and capital raising activity.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following: increased labor costs and historically low unemployment; increases in market interest rates and inflation; pandemics or epidemics, including COVID-19, and the related impact on our tenants, borrowers and senior housing - managed communities; operational risks with respect to our senior housing - managed communities; competitive conditions in our industry; the loss of key management personnel; uninsured or underinsured losses affecting our properties; potential impairment charges and adjustments related to the accounting of our assets; the potential variability of our reported rental and related revenues as a result of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs; risks associated with our investment in our unconsolidated joint ventures; catastrophic weather and other natural or man-made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures; increased operating costs and competition for our tenants, borrowers and senior housing - managed communities; increased healthcare regulation and enforcement; our tenants’ dependency on reimbursement from governmental and other third-party payor programs; the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent; our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties; the impact of litigation and rising insurance costs on the business of our tenants; the impact of required regulatory approvals of transfers of healthcare properties; environmental compliance costs and liabilities associated with real estate properties we own; our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws, or a material breach of our or our tenants’, borrowers’ or operators’ information technology; our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; the significant amount of and our ability to service our indebtedness; covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms; adverse changes in our credit ratings; our ability to make dividend distributions at expected levels; our ability to raise capital through equity and debt financings; changes and uncertainty in macroeconomic conditions and disruptions in the financial markets; risks associated with our ownership of property outside the U.S., including currency fluctuations; the relatively illiquid nature of real estate investments; our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws; compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; changes in tax laws and regulations affecting REITs; the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and the exclusive forum provisions in our bylaws.

Additional information concerning risks and uncertainties that could affect our business can be found in our filings with the Securities and Exchange Commission (the “SEC”), including in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, unless required by law to do so.

TENANT AND BORROWER INFORMATION

This release includes information regarding certain of our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this release has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.

NOTE REGARDING NON-GAAP FINANCIAL MEASURES

This release includes the following financial measures defined as non-GAAP financial measures by the SEC: Net Debt to Adjusted EBITDA, funds from operations (“FFO”), Normalized FFO, Adjusted FFO (“AFFO”), Normalized AFFO, FFO per diluted common share, Normalized FFO per diluted common share, AFFO per diluted common share, Normalized AFFO per diluted common share, net operating income (“NOI”) and Cash NOI. These measures may be different than non-GAAP financial measures used by other companies, and the presentation of these measures is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with U.S. generally accepted accounting principles. An explanation of these non-GAAP financial measures is included under “Reporting Definitions” in this release, and reconciliations of these non-GAAP financial measures to the GAAP financial measures we consider most comparable are included on the Investors section of our website at https://ir.sabrahealth.com/investors/financials/quarterly-results.

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(dollars in thousands, except per share data)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenues:

 

 

 

 

 

 

 

Rental and related revenues (1)

$

94,555

 

 

$

93,085

 

 

$

285,427

 

 

$

283,229

 

Resident fees and services

 

73,746

 

 

 

59,748

 

 

 

207,716

 

 

 

174,897

 

Interest and other income

 

9,700

 

 

 

8,794

 

 

 

27,746

 

 

 

25,991

 

Total revenues

 

178,001

 

 

 

161,627

 

 

 

520,889

 

 

 

484,117

 

Expenses:

 

 

 

 

 

 

 

Depreciation and amortization

 

42,720

 

 

 

43,242

 

 

 

127,315

 

 

 

140,211

 

Interest

 

29,467

 

 

 

28,156

 

 

 

87,189

 

 

 

85,024

 

Triple-net portfolio operating expenses

 

4,270

 

 

 

4,304

 

 

 

12,992

 

 

 

13,243

 

Senior housing - managed portfolio operating expenses

 

54,234

 

 

 

44,523

 

 

 

154,258

 

 

 

132,124

 

General and administrative

 

12,404

 

 

 

10,759

 

 

 

37,035

 

 

 

30,793

 

(Recovery of) provision for loan losses

 

(148

)

 

 

328

 

 

 

(446

)

 

 

549

 

Impairment of real estate

 

 

 

 

 

 

 

18,472

 

 

 

7,064

 

Total expenses

 

142,947

 

 

 

131,312

 

 

 

436,815

 

 

 

409,008

 

Other income (expense):

 

 

 

 

 

 

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

(1,541

)

Other income

 

 

 

 

2,229

 

 

 

838

 

 

 

2,570

 

Net loss on sales of real estate

 

(5,745

)

 

 

(46,545

)

 

 

(3,969

)

 

 

(75,893

)

Total other expense

 

(5,745

)

 

 

(44,316

)

 

 

(3,131

)

 

 

(74,864

)

Income (loss) before income (loss) from unconsolidated joint ventures and income tax benefit (expense)

 

29,309

 

 

 

(14,001

)

 

 

80,943

 

 

 

245

 

Income (loss) from unconsolidated joint ventures

 

214

 

 

 

(645

)

 

 

(301

)

 

 

(2,136

)

Income tax benefit (expense)

 

265

 

 

 

(455

)

 

 

(625

)

 

 

(1,509

)

Net income (loss)

$

29,788

 

 

$

(15,101

)

 

$

80,017

 

 

$

(3,400

)

 

 

 

 

 

 

 

 

Net income (loss), per:

 

 

 

 

 

 

 

Basic common share

$

0.13

 

 

$

(0.07

)

 

$

0.34

 

 

$

(0.01

)

Diluted common share

$

0.13

 

 

$

(0.07

)

 

$

0.34

 

 

$

(0.01

)

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding, basic

 

234,290,187

 

 

 

231,224,692

 

 

 

232,459,388

 

 

 

231,197,375

 

Weighted average number of common shares outstanding, diluted

 

237,043,400

 

 

 

231,224,692

 

 

 

234,777,101

 

 

 

231,197,375

 

(1)

See the following page for additional details regarding rental and related revenues.

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - SUPPLEMENTAL INFORMATION

(in thousands)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Cash rental income

$

91,829

 

 

$

88,006

 

 

$

273,955

 

 

$

265,044

 

Straight-line rental income

 

1,119

 

 

 

796

 

 

 

3,383

 

 

 

3,561

 

Write-offs of cash and straight-line rental income receivable and lease intangibles

 

(3,086

)

 

 

(939

)

 

 

(5,539

)

 

 

(1,372

)

Above/below market lease amortization

 

1,212

 

 

 

1,456

 

 

 

3,634

 

 

 

4,592

 

Operating expense recoveries

 

3,481

 

 

 

3,766

 

 

 

9,994

 

 

 

11,404

 

Rental and related revenues

$

94,555

 

 

$

93,085

 

 

$

285,427

 

 

$

283,229

 

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)

 

 

September 30, 2024

 

December 31, 2023

Assets

 

 

 

Real estate investments, net of accumulated depreciation of $1,125,470 and $1,021,086 as of September 30, 2024 and December 31, 2023, respectively

$

4,574,268

 

 

$

4,617,261

 

Loans receivable and other investments, net

 

441,825

 

 

 

420,624

 

Investment in unconsolidated joint ventures

 

130,811

 

 

 

136,843

 

Cash and cash equivalents

 

63,004

 

 

 

41,285

 

Restricted cash

 

5,972

 

 

 

5,434

 

Lease intangible assets, net

 

28,790

 

 

 

30,897

 

Accounts receivable, prepaid expenses and other assets, net

 

121,456

 

 

 

133,806

 

Total assets

$

5,366,126

 

 

$

5,386,150

 

Liabilities

 

 

 

Secured debt, net

$

45,817

 

 

$

47,301

 

Revolving credit facility

 

152,558

 

 

 

94,429

 

Term loans, net

 

535,984

 

 

 

537,120

 

Senior unsecured notes, net

 

1,735,848

 

 

 

1,735,253

 

Accounts payable and accrued liabilities

 

122,805

 

 

 

136,981

 

Lease intangible liabilities, net

 

28,270

 

 

 

32,532

 

Total liabilities

 

2,621,282

 

 

 

2,583,616

 

Equity

 

 

 

Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2024 and December 31, 2023

 

 

 

 

 

Common stock, $0.01 par value; 500,000,000 shares authorized, 236,586,805 and 231,266,020 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

 

2,366

 

 

 

2,313

 

Additional paid-in capital

 

4,574,707

 

 

 

4,494,755

 

Cumulative distributions in excess of net income

 

(1,849,168

)

 

 

(1,718,279

)

Accumulated other comprehensive income

 

16,939

 

 

 

23,745

 

Total equity

 

2,744,844

 

 

 

2,802,534

 

Total liabilities and equity

$

5,366,126

 

 

$

5,386,150

 

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

Cash flows from operating activities:

 

 

 

Net income (loss)

$

80,017

 

 

$

(3,400

)

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

127,315

 

 

 

140,211

 

Non-cash rental and related revenues

 

(2,229

)

 

 

(6,781

)

Non-cash interest income

 

24

 

 

 

(380

)

Non-cash interest expense

 

8,750

 

 

 

9,179

 

Stock-based compensation expense

 

6,448

 

 

 

5,468

 

Loss on extinguishment of debt

 

 

 

 

1,541

 

(Recovery of) provision for loan losses

 

(446

)

 

 

549

 

Net loss on sales of real estate

 

3,969

 

 

 

75,893

 

Impairment of real estate

 

18,472

 

 

 

7,064

 

Loss from unconsolidated joint ventures

 

301

 

 

 

2,136

 

Distributions of earnings from unconsolidated joint ventures

 

3,754

 

 

 

1,705

 

Other non-cash items

 

 

 

 

(3,704

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, prepaid expenses and other assets, net

 

(13,589

)

 

 

(10,660

)

Accounts payable and accrued liabilities

 

(2,213

)

 

 

3,013

 

Net cash provided by operating activities

 

230,573

 

 

 

221,834

 

Cash flows from investing activities:

 

 

 

Acquisition of real estate

 

(112,225

)

 

 

(39,630

)

Origination and fundings of loans receivable

 

(21,540

)

 

 

(9,614

)

Origination and fundings of preferred equity investments

 

(2,529

)

 

 

(11,015

)

Additions to real estate

 

(39,189

)

 

 

(63,794

)

Repayments of loans receivable

 

2,776

 

 

 

8,674

 

Repayments of preferred equity investments

 

5,322

 

 

 

4,828

 

Investment in unconsolidated joint ventures

 

(717

)

 

 

(4,797

)

Net proceeds from the sales of real estate

 

40,541

 

 

 

248,222

 

Net proceeds from sales-type lease

 

 

 

 

25,490

 

Insurance proceeds

 

 

 

 

6,001

 

Distributions in excess of earnings from unconsolidated joint ventures

 

 

 

 

544

 

Net cash (used in) provided by investing activities

 

(127,561

)

 

 

164,909

 

Cash flows from financing activities:

 

 

 

Net borrowings from (repayments of) revolving credit facility

 

58,815

 

 

 

(165,338

)

Proceeds from term loans

 

 

 

 

12,188

 

Principal payments on secured debt

 

(1,520

)

 

 

(1,479

)

Payments of deferred financing costs

 

(80

)

 

 

(18,135

)

Payment of contingent consideration

 

 

 

 

(17,900

)

Issuance of common stock, net

 

71,362

 

 

 

(2,194

)

Dividends paid on common stock

 

(209,174

)

 

 

(208,079

)

Net cash used in financing activities

 

(80,597

)

 

 

(400,937

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

22,415

 

 

 

(14,194

)

Effect of foreign currency translation on cash, cash equivalents and restricted cash

 

(158

)

 

 

(880

)

Cash, cash equivalents and restricted cash, beginning of period

 

46,719

 

 

 

53,932

 

Cash, cash equivalents and restricted cash, end of period

$

68,976

 

 

$

38,858

 

Supplemental disclosure of cash flow information:

 

 

 

Interest paid

$

71,632

 

 

$

72,911

 

Supplemental disclosure of non-cash investing activities:

 

 

 

Decrease in loans receivable and other investments due to acquisition of real estate

$

 

 

$

4,644

 

SABRA HEALTH CARE REIT, INC.

FUNDS FROM OPERATIONS (FFO), NORMALIZED FFO,

ADJUSTED FUNDS FROM OPERATIONS (AFFO) AND NORMALIZED AFFO

(dollars in thousands, except per share data)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net income (loss)

$

29,788

 

 

$

(15,101

)

 

$

80,017

 

 

$

(3,400

)

Add:

 

 

 

 

 

 

 

Depreciation and amortization of real estate assets

 

42,720

 

 

 

43,242

 

 

 

127,315

 

 

 

140,211

 

Depreciation, amortization and impairment of real estate assets related to unconsolidated joint ventures

 

2,243

 

 

 

2,255

 

 

 

6,680

 

 

 

6,505

 

Net loss on sales of real estate

 

5,745

 

 

 

46,545

 

 

 

3,969

 

 

 

75,893

 

Impairment of real estate

 

 

 

 

 

 

 

18,472

 

 

 

7,064

 

FFO

$

80,496

 

 

$

76,941

 

 

$

236,453

 

 

$

226,273

 

Write-offs of cash and straight-line rental income receivable and lease intangibles

 

3,086

 

 

 

939

 

 

 

5,539

 

 

 

1,371

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

1,541

 

(Recovery of) provision for loan losses

 

(148

)

 

 

328

 

 

 

(446

)

 

 

549

 

Other normalizing items (1)

 

119

 

 

 

(1,003

)

 

 

2,718

 

 

 

1,066

 

Normalized FFO

$

83,553

 

 

$

77,205

 

 

$

244,264

 

 

$

230,800

 

FFO

$

80,496

 

 

$

76,941

 

 

$

236,453

 

 

$

226,273

 

Stock-based compensation expense

 

2,586

 

 

 

2,235

 

 

 

6,448

 

 

 

5,468

 

Non-cash rental and related revenues

 

(433

)

 

 

(1,312

)

 

 

(2,229

)

 

 

(6,781

)

Non-cash interest income

 

12

 

 

 

8

 

 

 

24

 

 

 

(380

)

Non-cash interest expense

 

2,611

 

 

 

3,088

 

 

 

8,750

 

 

 

9,179

 

Non-cash portion of loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

1,541

 

(Recovery of) provision for loan losses

 

(148

)

 

 

328

 

 

 

(446

)

 

 

549

 

Other adjustments related to unconsolidated joint ventures

 

113

 

 

 

133

 

 

 

401

 

 

 

371

 

Other adjustments

 

353

 

 

 

256

 

 

 

1,192

 

 

 

950

 

AFFO

$

85,590

 

 

$

81,677

 

 

$

250,593

 

 

$

237,170

 

Write-off of cash rental income

 

1,189

 

 

 

 

 

 

751

 

 

 

 

Other normalizing items (1)

 

113

 

 

 

(1,017

)

 

 

2,549

 

 

 

1,021

 

Normalized AFFO

$

86,892

 

 

$

80,660

 

 

$

253,893

 

 

$

238,191

 

Amounts per diluted common share:

 

 

 

 

 

 

 

Net income (loss)

$

0.13

 

 

$

(0.07

)

 

$

0.34

 

 

$

(0.01

)

FFO

$

0.34

 

 

$

0.33

 

 

$

1.01

 

 

$

0.97

 

Normalized FFO

$

0.35

 

 

$

0.33

 

 

$

1.04

 

 

$

0.99

 

AFFO

$

0.36

 

 

$

0.35

 

 

$

1.06

 

 

$

1.01

 

Normalized AFFO

$

0.37

 

 

$

0.34

 

 

$

1.08

 

 

$

1.02

 

Weighted average number of common shares outstanding, diluted:

 

 

 

 

 

 

Net income (loss)

 

237,043,400

 

 

 

231,224,692

 

 

 

234,777,101

 

 

 

231,197,375

 

FFO and Normalized FFO

 

237,043,400

 

 

 

232,835,849

 

 

 

234,777,101

 

 

 

232,566,392

 

AFFO and Normalized AFFO

 

237,940,868

 

 

 

233,988,463

 

 

 

235,890,966

 

 

 

233,878,874

 

(1)

Other normalizing items for FFO and AFFO primarily include triple-net operating expenses, net of recoveries.

Adjusted EBITDA*

Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation and amortization (“EBITDA”) excluding the impact of merger-related costs, stock-based compensation expense under the Company’s long-term equity award program, and loan loss reserves. Adjusted EBITDA is an important non-GAAP supplemental measure of operating performance.

Behavioral Health

Includes behavioral hospitals that provide inpatient and outpatient care for patients with mental health conditions, chemical dependence or substance addictions and addiction treatment centers that provide treatment services for chemical dependence and substance addictions, which may include inpatient care, outpatient care, medical detoxification, therapy and counseling.

Cash Net Operating Income (“Cash NOI”)

The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company considers Cash NOI an important supplemental measure because it allows investors, analysts and its management to evaluate the operating performance of its investments. The Company defines Cash NOI as total revenues less operating expenses and non-cash revenues and expenses. Cash NOI excludes all other financial statement amounts included in net income.

EBITDARM

Earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) for a particular facility accruing to the operator/tenant of the property (not the Company), for the period presented. The Company uses EBITDARM in determining EBITDARM Coverage. EBITDARM has limitations as an analytical tool. EBITDARM does not reflect historical cash expenditures or future cash requirements for facility capital expenditures or contractual commitments. In addition, EBITDARM does not represent a property’s net income or cash flows from operations and should not be considered an alternative to those indicators. The Company utilizes EBITDARM to evaluate the core operations of the properties by eliminating management fees, which may vary by operator/tenant and operating structure, and as a supplemental measure of the ability of the Company’s operators/tenants and relevant guarantors to generate sufficient liquidity to meet related obligations to the Company.

EBITDARM Coverage

Represents the ratio of EBITDARM to cash rent for owned facilities (excluding Senior Housing - Managed communities) for the period presented. EBITDARM Coverage is a supplemental measure of a property’s ability to generate cash flows for the operator/tenant (not the Company) to meet the operator’s/tenant’s related cash rent and other obligations to the Company. However, its usefulness is limited by, among other things, the same factors that limit the usefulness of EBITDARM. EBITDARM Coverage includes only Stabilized Facilities and excludes facilities for which data is not available or meaningful.

Funds From Operations (“FFO”) and Adjusted Funds from Operations (“AFFO”)*

The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company also believes that funds from operations, or FFO, as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations, or AFFO (and related per share amounts) are important non-GAAP supplemental measures of the Company’s operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a real estate investment trust that uses historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for real estate investment trusts that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net income, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and the Company’s share of gains or losses from real estate dispositions related to its unconsolidated joint ventures, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus the Company’s share of depreciation and amortization related to its unconsolidated joint ventures, and real estate impairment charges of both consolidated and unconsolidated entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. AFFO is defined as FFO excluding stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for (recovery of) loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including noncapitalizable acquisition costs, transaction costs related to operator transitions and organizational or other restructuring activities, ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and the Company’s share of non-cash adjustments related to its unconsolidated joint ventures. The Company believes that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of the Company’s operating results among investors and makes comparisons of operating results among real estate investment trusts more meaningful. The Company considers FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare the operating performance of the Company between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of real estate investment trusts, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company’s liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to the Company’s real estate assets nor do they purport to be indicative of cash available to fund the Company’s future cash requirements. Further, the Company’s computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other real estate investment trusts that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than the Company does.

Investment

Represents the carrying amount of real estate assets after adding back accumulated depreciation and amortization and excludes net intangible assets and liabilities.

Net Debt*

The principal balances of the Company’s revolving credit facility, term loans, senior unsecured notes, and secured indebtedness as reported in the Company’s consolidated financial statements, net of cash and cash equivalents as reported in the Company’s consolidated financial statements.

Net Debt to Adjusted EBITDA*

Net Debt to Adjusted EBITDA is calculated as Net Debt divided by Annualized Adjusted EBITDA, which is Adjusted EBITDA, as adjusted for annualizing adjustments that give effect to the acquisitions and dispositions completed during the respective period as though such acquisitions and dispositions were completed as of the beginning of the period presented.

Net Operating Income (“NOI”)*

The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company considers NOI an important supplemental measure because it allows investors, analysts and its management to evaluate the operating performance of its investments. The Company defines NOI as total revenues less operating expenses. NOI excludes all other financial statement amounts included in net income.

Normalized FFO and Normalized AFFO*

Normalized FFO and Normalized AFFO represent FFO and AFFO, respectively, adjusted for certain income and expense items that the Company does not believe are indicative of its ongoing operating results. The Company considers Normalized FFO and Normalized AFFO to be useful measures to evaluate the Company’s operating results excluding these income and expense items to help investors compare the operating performance of the Company between periods or as compared to other companies. Normalized FFO and Normalized AFFO do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company’s liquidity or operating performance. Normalized FFO and Normalized AFFO also do not consider the costs associated with capital expenditures related to the Company’s real estate assets nor do they purport to be indicative of cash available to fund the Company’s future cash requirements. Further, the Company’s computation of Normalized FFO and Normalized AFFO may not be comparable to Normalized FFO and Normalized AFFO reported by other real estate investment trusts that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define FFO and AFFO or Normalized FFO and Normalized AFFO differently than the Company does.

Senior Housing

Senior Housing communities include independent living, assisted living, continuing care retirement and memory care communities.

Senior Housing - Managed

Senior Housing communities operated by third-party property managers pursuant to property management agreements.

Skilled Nursing/Transitional Care

Skilled Nursing/Transitional Care facilities include skilled nursing, transitional care, multi-license designation and mental health facilities.

Specialty Hospitals and Other

Includes acute care, long-term acute care and rehabilitation hospitals, facilities that provide residential services, which may include assistance with activities of daily living, and other facilities not classified as Skilled Nursing/Transitional Care, Senior Housing or Behavioral Health.

Stabilized Facility

At the time of acquisition, the Company classifies each facility as either stabilized or non-stabilized. In addition, the Company may classify a facility as non-stabilized after acquisition. Circumstances that could result in a facility being classified as non-stabilized include newly completed developments, facilities undergoing major renovations or additions, facilities being repositioned or transitioned to new operators, and significant transitions within the tenants’ business model. Such facilities are typically reclassified to stabilized upon the earlier of maintaining consistent performance or 24 months after the date of classification as non-stabilized. Stabilized Facilities generally exclude (i) facilities held for sale, (ii) strategic disposition candidates, (iii) facilities being transitioned to a new operator, (iv) facilities being transitioned from being leased by the Company to being operated by the Company and (v) leased facilities acquired during the three months preceding the period presented.

*Non-GAAP Financial Measures

Reconciliations, definitions and important discussions regarding the usefulness and limitations of the Non-GAAP Financial Measures used in this release can be found at https://ir.sabrahealth.com/investors/financials/quarterly-results.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.